Mpox vaccination coverage in the Democratic Republic of Congo: A systematic review and meta-analysis of uptake and acceptance (1970–2024)

Fabrice Zobel Lekeumo Cheuyem[1]*, Adidja Amani[1], Adamu Abubakar Umar[2], Chabeja Achangwa[3], Brian Ngongheh Ajong[4], Solange Dabou[5], Jessy Goupeyou-Youmsi[5], Guy Roger Pilo Ndibo[6], Rick Tchamani[7], Ethel Ambo Eno[8], Jonathan Hangi Ndungo[9], Saralees Nadarajah[3]

[1] Department of Public Health, Faculty of Medicine and Biomedical Sciences, The University of Yaoundé 1, Yaoundé, Cameroon

[2] Department of Mathematics, University of Manchester, Manchester, UK

[3] Department of Public Health, Faculty of Medical Sciences, University of West Indies, Bridgetown, Barbados

[4] Health Emergencies Programme, World Health Organization, Kinshasa, Democratic Republic of Congo

[5] Division of Health Policy and Research, Nkafu Policy Institute, Denis and Lenora Foretia Foundation, Yaoundé, Cameroon

[6] Military Health Directorate, Ministry of Defense, Yaoundé, Cameroon

[7] Rosière Higher School of Health Sciences, Yaoundé, Cameroon

[8] Women in Global Health, Yaoundé, Cameroon

[9] Higher Institute of Medical Techniques, Bunia, Democratic Republic of Congo

***Corresponding author's address**:

Fabrice Zobel Lekeumo Cheuyem,

Tel: +237 696 57 28 07;

E-mail: zobelcheuyem@gmail.com

ORCID: 0000-0003-4047-8829.

Abstract

Background The Democratic Republic of Congo (DRC) is recognized as the global epicenter of human Mpox. While vaccination is crucial for outbreak prevention, especially as the disease transitions from zoonotic spillover to sustained human-to-human transmission, comprehensive assessments of vaccination coverage trends across the country are notably absent from the literature. This systematic review and meta-analysis address this gap by providing the first pooled estimate of Mpox vaccine uptake and acceptance in the DRC over a 54-year period (1970-2024). Our study captures critical transitions, including the post-smallpox eradication era and recent global outbreaks, to identify temporal trends, geographic disparities in this high-risk setting.

Methods We conducted this review following PRISMA guidelines, systematically searching PubMed, Scopus, ScienceDirect, Web of Sciences, CINAHL, and Embase. Grey literature was also searched to ensure comprehensiveness. Using random-effects models, we calculated pooled estimates for vaccine uptake and acceptance rates, with prespecified subgroup analyses examining variations by: (1) period, (2) geographic region, and (3) type of participants. We quantified heterogeneity using I^2 statistics and conducted meta-regression to identify predictors of vaccination coverage heterogeneity. A p-value ≤ 0.05 was considered statistically significant.

Results Our analysis revealed a pooled Mpox vaccine uptake of 20.01% (95% CI: 7.45–43.75) with high heterogeneity (I^2 = 99.4%, $p < 0.001$), indicating substantial variability across studies. Vaccine acceptance was higher at 54.17% (95% CI: 20.82–84.16) with high heterogeneity (I^2 = 97.6%, $p < 0.001$). Temporal analysis showed a significant decline from 32.30% (95% CI: 14.62–57.75) coverage during 1970–2000 to 1.36% (95% CI: 0.29–6.11) in 2020–2024. Geographic disparities existed, with the Northwest regions achieving 47.11% (95% CI: 13.46–83.61) coverage compared to 5.47% (95% CI: 0.56–37.32) in Eastern conflict-affected zones. Meta-regression identified no significant predictors of coverage heterogeneity.

Conclusion Despite moderate acceptance rates, actual Mpox vaccination uptake in the DRC remains critically low, with worsening coverage in recent years and substantial regional inequities. These findings underscore the urgent need for context-specific interventions to bridge the intention-action gap in this high-risk setting.

Keywords Monkeypox, vaccine, uptake, acceptance, Democratic Republic of Congo, systematic review, meta-analysis

Background

Mpox, previously termed monkeypox, is a zoonotic disease stemming from the monkeypox virus [1]. Before 2022, its presence was confined mainly to secluded rainforest communities in the western and central parts of Africa [2]. The virus spreads through direct contact with infected animals or humans, including sexual or skin-to-skin contact, respiratory droplets, and contaminated objects like clothing, towels, and bedding [3,4]. The most recent Mpox outbreak was initially declared in the UK on May 7, 2022, and the contagion has disseminated to other continents beyond Africa [5]. Subsequently, the disease outbreak was declared as a Public Health Emergency of International Concern on July 23, 2022 [6]. There are two types of Mpox, clade I and clade II. The ongoing global outbreak that started in 2022 is caused by clade II. The current epidemic in Eastern and Central Africa caused by clade I Mpox [7].

The Democratic Republic of Congo (DRC) has been the epicenter of human Mpox since the virus's first identification in 1970 [2]. The current resurgence in the Democratic Republic of Congo (DRC) is linked to clade Ib, which appears to be spreading more rapidly through sexual contact and is associated with more virulent manifestations of the disease, especially in pediatric populations and immunodeficient patients [8,9]. Mpox demonstrates considerable disease severity and has caused significant mortality in the Democratic Republic of Congo [10]. To address this disease severity and save lives, the global health and scientific community has developed and deployed several vaccines for Mpox in the DRC, the disease's most endemic focus worldwide [1,11].

Developing new vaccines for widespread use against Mpox and its emerging strains is a critical preventive strategy in the ongoing battle against this dynamic infection [12]. The smallpox vaccine has

undergone three generations of technological advancements, with only the second and third versions now licensed. Three orthopoxviral vaccines are available: ACAM2000, JYNNEOS, and LC16m8 [12]. A substantial genetic homology exists between smallpox and Mpox, evidenced by shared immunological epitopes and markers. Owing to this close relationship, various studies indicate that smallpox vaccines confer robust cross-immunity against Mpox [13]. Furthermore, hypotheses have been advanced that the observed escalation in Mpox prevalence is attributable to a progressively immunologically naive global population, stemming directly from the cessation of smallpox immunization campaigns [14].

Despite four decades of Mpox surveillance, vaccination coverage remains poorly characterized across this vast area. Multiple studies reveal variable temporal trends, geographic disparities, and disparities in healthcare access, especially in conflict-affected regions [1,2,11,15–21]. The DRC's health system - fragmented by decades of instability [5] - faces unique challenges in delivering vaccines to remote endemic zones like Equateur and Kivu [22]. Therefore, public health systems must take decisive action to prevent the global spread of Mpox, particularly among vulnerable groups [23]. This systematic review and meta-analysis on Mpox vaccination uptake and acceptance in Africa addresses critical evidence gaps in understanding immunization patterns across the continent's highest-burden regions. As the Democratic Republic of Congo (DRC) reports over 80% of global Mpox cases, characterizing vaccine coverage dynamics becomes essential for outbreak response. There is a need for temporal trends following smallpox vaccination cessation, (2) geographic disparities exacerbated by conflict and healthcare access inequalities, and (3) the intention-action gap between vaccine acceptance and actual uptake. Our study addresses these knowledge gaps through the first comprehensive, half-century analysis of Mpox vaccination trends in the DRC. By synthesizing data from 1970 to 2024, we quantified temporal changes in coverage post-smallpox eradication, mapped regional inequities and assessed acceptance-uptake disparity. These insights will inform targeted vaccination strategies in this complex, high-priority setting.

Methods

Study design

This systematic review and meta-analysis examine the vaccination uptake and acceptance in the DRC between 1970 and 2024. The study was reported following the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines [24].

Study setting

The DRC, the largest country in Sub-Saharan Africa, spans approximately 2,345,409 km^2 [25]. It shares borders with nine countries (Angola, Burundi, the Central African Republic, the Republic of Congo, Rwanda, South Sudan, Tanzania, Uganda, and Zambia) 26]. The DRC comprises 26 provinces, including Kinshasa (the capital), Nord-Kivu, Sud-Kivu, Equateur, Tshuapa, and Bas-Huélé among others [10]. The health system is structured into three tiers: central, intermediate, and operational levels, with 519 health zones, 393 general referral hospitals, and 8,504 health areas delivering primary care [27]. With a population exceeding 105 million, the DRC has a median age of 16.7 years, a growth rate of 3.1%, and a life expectancy of 61.6 years [28]. The country faces recurrent infectious disease outbreaks, including Mpox, Ebola, Cholera, Measles and , Yellow fever, exacerbated by humanitarian crises linked to protracted civil unrest and armed conflict [29]. Socio-culturally, over 93% of the population identifies as Christian, with Catholics representing 42% [30]. These demographic, health, and geopolitical factors collectively shape the DRC's unique challenges in disease surveillance and outbreak response [31].

Eligibility criteria

Inclusion criteria: All observational studies addressing Mpox vaccine uptake and intention to vaccinate among general population, healthcare workers or other at-risk populations were included. No limitations were applied regarding language or time period. However, only those studies that were fully available, included sample size details, and presented relevant data on any aspect related to Mpox vaccine acceptance and uptake were included.

Exclusion criteria: Studies were deemed ineligible for inclusion if their research focus diverged from our investigative objectives or if their methodology differed from an observational design. Furthermore,

incomplete articles were not considered, especially those characterized by insufficient data or an absence of the requisite results.

Article searching strategy

Published research was identified through a systematic search on online databases, including PubMed, CINAHL, Embase, Web of Science, Scopus, ScienceDirect, and AJOL. The search process involved examining titles and abstracts using a keywords and Medical Subject Headings (MeSH). Boolean operators ("AND" and "OR") were employed to refine the search as follow: “Mpox” OR “mpox” OR “Monkeypox” AND “vaccine” OR “vaccination” OR “acceptance” AND “DRC” OR “Democratic Republic of Congo” OR “Zaire” (Supplementary Table 1). A manual search for grey literature and additional publications not indexed in these databases was conducted in and Google Scholar (first 1000 entries assessed and no filter applied) to ensure comprehensive coverage. Furthermore, the reference lists of included studies were screened for relevant articles. The final search was completed on February 27, 2025.

Data extraction

Data was extracted from all eligible articles using a pre-designed Microsoft Excel 2016 form to collect study characteristics. This form captured the first author's name, study year, region, study design, study type, type of participant, setting, number of individuals willing to receive the vaccine, number of individuals who received the vaccine, and the sample size. Two authors independently assessed the relevance and quality of each article. Any disagreements between the reviewers were resolved through discussion with a third author to reach a consensus.

Data quality assessment

The Joanna Briggs Institute (JBI) quality assessment tool was used to evaluate the quality of the studies included 32]. For cross-sectional studies, assessment criteria encompassed studies clear definition of inclusion criteria, comprehensive descriptions of study subjects and settings, validity and reliability of exposure measurements, use of objective, standardized criteria for outcome assessment, identification potential confounding factors, implementation of appropriate strategies to address them, and the appropriateness of

statistical methods. For cohort study, this evaluation examined group comparability between exposed and unexposed populations, consistency and accuracy of exposure measurement, identification and adjustment for confounding factors, and confirmation of outcome-free status at baseline. The appraisal also considered validity of outcome measurement, adequacy and completeness of follow-up duration, strategies to address incomplete follow-up, and appropriateness of statistical analysis. Each criterion was scored as 1 (yes) or 0 (no or unclear). The overall risk of bias was categorized based on the proportion of criteria met as follow: low (>50%), moderate (>25-50%), or high (≤25%).

Outcome measurement

The primary outcomes of this systematic review and meta-analysis were the Mpox vaccination uptake and the secondary outcome included the Mpox vaccine acceptance. The Mpox vaccine uptake and acceptance rate were calculated by dividing the number of people who received the vaccine and those who intended to receive it by the total number of participants.

Operational definition

The vaccination uptake were measured in included studies base on the declaration of having received an Mpox vaccine or presented a Mpox vaccination card or a scar characteristic of the smallpox vaccine injection 15]. Meanwhile, the Mpox acceptance referred to the intention, defined as the unconditional willingness to receive the free Mpox vaccine if offered [11,33].

Statistical analysis and synthesis

The Higgin's I^2 statistic was used to assess the heterogeneity between studies, categorizing heterogeneity as none (0%), low (<25%), moderate (25-75%), or high (>75%). Subgroup analyses were then conducted based on study period, region, setting, type of participants. Given the substantial heterogeneity observed across studies, reflecting divergent regional, temporal, and methodological contexts in Mpox vaccination data from the DRC, a random-effects model was selected to account for true variation in effect sizes beyond sampling error alone. This approach ensures that pooled estimates generalize to the broader population while conservatively weighting studies and acknowledging uncertainty introduced by underlying differences in study

designs, populations, and implementation settings. Furthermore, meta-regression explored whether study characteristics including study year, location (region) and setting explained the variability in results. For subgroup analysis, the timeframe was divided into specific periods, including the smallpox vaccine era, 2010–2019: limited Mpox vaccine interest; 2020–2024: increased focus due to global outbreaks. The regions were grouped into geographical specific group including the Northwest endemic zone (historically high Mpox transmission zone encompassed Equateur, Tshuapa and Bas-Uélé); the Central/South endemic zone (moderate Mpox activity comprised Sankuru and Kasai Oriental); and the Easthern conflict affected zone (lower Mpox activity but high population movement included South Kivu, North Kivu and Tshopo). Generalized Linear Mixed Models (GLMM), coupled with the Probit-Logit Transformation (PLOGIT) were used as they are ideal for meta-analyses of binary or proportion data as they directly model binomial outcomes, effectively account for between-study heterogeneity using random effects, and inherently handle studies with 0% or 100% events without requiring continuity corrections 34]. Statistical significance was set at a p-value of <0.05. All analyses were performed using the 'meta' package in R Statistics version [4.4.2 35].

Publication bias and sensitivity test

Publication bias was assessed visually using a funnel plot. The symmetry of the inverted funnel shape suggested the absence of publication bias. The Egger's and Begg's tests were also performed to test the significance any visually assessed publication bias. Sensitivity analysis was conducted by iteratively excluding one study at a time to assess the robustness of the findings. This tested the robustness of our primary meta-analysis results to potential outliers, particularly given the high heterogeneity potential. By iteratively excluding each study, we aimed to quantify how removal of specific studies (e.g., those with extreme proportions or large sample sizes) altered the pooled estimate and determine if conclusions remained consistent across methodological variations.

Results

A total of 1,845 entries were obtained through an online database search (n = 1,796) and a manual search (n = 49). After removing 167 redundant entries, 1,678 distinct entries underwent title and abstract review, followed

by a complete text evaluation for suitability. Ultimately, 18 reports satisfied the inclusion criteria and were incorporated into the meta-analysis (Fig. 1).

Studies selection



Fig. 1 PRISMA diagram flow of studies included in the meta-analysis

Characteristics of studies included

Eighteen studies carried out in community and hospital settings across the DRC between 1970 and 2024, were included in this comprehensive analysis 1,2,11,15–21,36–43]. Most of these studies (n = 15) employed surveillance and investigation for data collection, focusing on the general population and healthcare workers to describe Mpox vaccination acceptance and uptake. Most of the studies (n = 16) presented a low risk of bias (Table 1).

Mpox vaccine uptake

A random effects meta-analysis of 17 studies (n = 8498 participants) estimated an overall Mpox vaccination uptake rate of 20.01% (95% CI: 7.45–43.75), with substantial heterogeneity (I^2=99.4%, p < 0.001). Study-specific rates ranged from 0% to 94.08% (Fig. 2).



Fig. 2 Pooled Mpox vaccination coverage estimate in DRC, 1970-2024

Mpox vaccine acceptance

A random effects meta-analysis of three studies (n = 5,388) yielded a pooled vaccine acceptance rate of 54.17% (95% CI: 20.82–84.16), with high heterogeneity (I^2=97.6%, p < 0.001). Individual study rates varied widely, from 18.92% (Nolen *et al.*, 2013) [42] to 85.71% (Petersen, *et al.*, 2014) [1], with the largest study (Petrichko *et al.*, 2024) [11] reporting 61.00% (95% CI: 59.66–62.33) (Fig. 3).



Fig. 3 Pooled Mpox vaccination acceptance estimates in DRC, 1970-2024

Subgroup analysis

The subgroup analysis revealed significant disparities in Mpox vaccination coverage across different periods, regions, and study designs in the DRC (1970–2024). The vaccination coverage was highest in earlier decades (32.30% in 1970–2000; 32.89% in 2001–2020) but decreased to 1.36% during 2021–2024, suggesting recent declines significantly (p = 0.001) in vaccination efforts. Geographically, Equateur (53.60%, n = 2 studies) and Bas-Uélé (92.96%, n = 1 study) had notably high coverage, while Sankuru (7.42%) and Tshopo (3.48%) lagged. Nationwide studies reported highly variable estimates (51.23%, 95% CI: 0–100%, n = 2 studies).

263

264

265

266

267

268

269 **Table 2** Subgroup analysis of Mpox vaccination coverage in DRC, 1970-2024

Subgroup	Sample size	Coverage (%)	95% CI limits		Number of studies	Heterogeneity statistic[1]	
Study period[2]			**Lower**	**Upper**		I^2(%)	*p*-value
1970-2000	5409	32.30	10.41	66.20	8	99.6	?0.001
2001-2020	2080	32.89	9.64	69.24	6	97.6	?0.001
2021-2024	1009	1.36	0.29	6.11	3	0.0	0.635
Study period[3]							
? 2022	7489	32.60	14.62	57.75	14	99.5	?0.001
2022+	1009	1.36	0.29	6.11	3	0.0	0.635
Region							
Equateur	1170	53.80	2.74	97.97	2	98.6	?0.001
Kasai Oriental	423	10.01	4.48	20.87	2	91.3	0.007
Sankuru	844	7.42	2.71	18.70	2	94.6	0.004
Tshuapa	1219	20.87	8.75	42.04	3	94.2	?0.001
Kivu (North and South)	1946	5.58	0.26	57.30	4	96.0	?0.001
Bas-Uélé	71	92.96	84.33	97.67	1	-	-
Tshopo	460	3.48	2.00	5.59	1	-	-
Nationwide	2365	53.36	5.16	96.00	2	99.8	?0.001
Zone[4]							
Northwest endemic zone	2460	47.11	13.46	83.61	6	99.5	?0.001
Central/South endemic zone	1267	8.63	4.46	16.04	4	91.3	?0.001
Eastern conflict-affected zone	2406	5.47	0.56	37.32	5	97.9	?0.001
Nationwide	2365	53.36	5.16	96.00	2	99.8	□0.001
Setting							
Community	8190	22.59	8.37	48.35	16	99.5	□0.001
Hospital	308	2.27	0.92	4.63	1	-	-
Participant							
General population	8336	18.37	5.86	44.82	15	99.5	□0.001
General population and Healthcare worker	148	21.61	15.28	29.13	1	-	-
Healthcare worker	14	50.00	23.04	76.96	1	-	-

[1] Random effects model; CI: Confidence interval; [2] 1970–2000: smallpox vaccine era; 2001–2020: Limited Mpox vaccine interest; 2021–2024: Increased

focus due to global outbreaks; [3] Period before and after the global outbreak declaration; [4] Northwest endemic zone (historically high Mpox transmission zone) = Equateur, Tshuapa and Bas-Uélé; Central/South endemic zone (moderate Mpox activity) = Sankuru and Kasai Oriental; Easthern conflict affected zone (lower Mpox activity but high population movement) = South Kivu, North Kivu and Tshopo.

Meta-regression analysis

The meta-regression analysis found no statistically significant predictors of Mpox vaccination coverage heterogeneity in the DRC (1970–2024). While the study year showed a marginal negative trend in univariate analysis (β = -0.0545, p = 0.078), suggesting a possible decline in coverage over time, this association was not significant after adjustment (β = -0.0427, p = 0.248). Similarly, region and setting (hospital vs. community) demonstrated no significant effects in either univariate or multivariate models (p > 0.1 for all) (Table 3).

Table 3 Meta-regression analysis of Mpox vaccination coverage and acceptance in DRC, 1970-2024

Estimate	Moderator	Univariate		Multivariate	
		Unadjusted coefficient (β)	*p*-value	Adjusted coefficient (β)	*p*-value
Vaccination uptake					
Study year	Year	-0.0545	0.078	-0.0427	0.248
Region	Region vs. Nationwide	-1.6282	0.341	-0.7019	0.700
Setting	Hospital vs. Community	-2.6276	0.258	-1.5533	0.530

Publication bias

While the left shift of the funnel plot suggested potential publication bias, Egger's test (p = 0.203) and Begg's test (p = 0.249) did not indicate any statistically significant bias (Fig. 4).



Fig. 4 Funnel plot with pseudo 95% confidence limits and tests assessing the publication bias of studies included

Sensitivity test analysis

Sensitivity analysis indicated that no single study significantly influences the pooled Mpox vaccination coverage estimate reflecting the robustness of the findings (Fig. 5).



Fig. 5 Sensitivity analysis of the pooled Mpox vaccination coverage in DRC, 1970-2024

Discussion

This systematic review and meta-analysis were primarily conducted to determine the Mpox vaccine uptake rate in the world's most endemic focus. It synthesized data from 18 studies to provide a comprehensive overview of the DRC from 1970 to 2024.

Vaccine uptake

This meta-analysis comprehensively assesses Mpox vaccination coverage in the DRC from 1970 to 2024, revealing critical insights into its temporal trends, regional disparities, and methodological challenges. The pooled estimate (20.01%, 95% CI: 7.45–43.75) and subgroup analyses demonstrated high heterogeneity (I^2 > 99.4%), reflecting wide variability in coverage across regions, periods, and study designs. Our results corroborated findings from a global meta-analysis of Mpox vaccine uptake, which revealed a pooled rate of 30.9% (95% CI: 21.0–41.7), but this was higher than that of the WHO African region at 5.0% (95% CI: 3.7–6.7) 33]. This highlights a substantial disparity in vaccine coverage between the African region and the global average. This vaccination profile could be attributed to structural barriers, including limited healthcare infrastructure, cold-chain challenges, and inequitable vaccine distribution in Africa, all of which reduce access compared to high-income regions with robust systems. Additionally, socioeconomic factors such as lower health literacy, vaccine hesitancy driven by mistrust, and competing health priorities further widen the gap in coverage [44,45].

Our analysis revealed a notable temporal trend in Mpox vaccination coverage within the DRC. Coverage was substantially higher in studies conducted between 1970 and 2000, with a pooled estimate of 32.30% (95% CI: 10.41-66.20). However, this figure plummeted to a mere 1.36% in studies conducted post-2020. This represents a significant reduction of over 95% in estimated vaccination coverage, indicating a critical shift in the landscape of Mpox prevention efforts. This decline may be associated with challenges in vaccine supply chains, reduced access to healthcare facilities, and a diversion of resources to outbreak response [46,47]. This likely contributed to the substantial decrease in routine vaccination activities. The significant drop in Mpox vaccination coverage post-2020 seriously affects public health in the DRC. Reduced

population immunity increases the risk of future outbreaks, potentially with greater severity and wider spread, particularly if healthcare systems remain strained [10,48].

To explore potential geographical variations in Mpox vaccination coverage, we conducted a stratified analysis across three distinct zones within the DRC: the Northwest endemic zone, the Central/South endemic zone, and the Eastern conflict-affected zone. Our study revealed significant disparities in pooled estimates across these regions. The Northwest endemic zone exhibited the highest estimated coverage/acceptance at 47.11% (95% CI: 13.46-83.61), while the Eastern conflict-affected zone showed a considerably lower estimate of 5.47 (95 CI: 0.56-37.32). The higher estimated coverage in the Northwest endemic zone could be attributed to the region's more extended history with Mpox outbreaks, potentially leading to greater community awareness and established vaccination programs over time [2,15]. The lower coverage observed in the Central/South endemic zone, or the Eastern conflict-affected zone, likely reflects differing healthcare priorities or access challenges compared to the Northwest. The complex interplay of conflict-related disruptions to healthcare access alongside potential targeted interventions by humanitarian organizations may also explain these findings [16,19].

Future research should prioritize comprehensive investigations into the intricate interplay of healthcare infrastructure, community engagement strategies, and the pervasive impact of conflict on vaccination efforts across different regions. By meticulously dissecting these nuances, we can pave the way for developing and implementing targeted, equitable, and ultimately more effective strategies to strengthen immunization programs in DRC.

Vaccine acceptance

Our study's pooled Mpox vaccine acceptance rate was 54.17% (95% CI: 20.82-84.16), consistent with a global meta-analysis and an African multinational study reporting acceptance rates from 51.1% to 74.4% [5,33]. However, we identified a substantial discrepancy between vaccine acceptance (54.17%) and actual uptake (20.01%), revealing a critical implementation gap in Mpox vaccination programs. This disparity likely results from multiple factors, including temporal variations in study periods and uneven vaccine availability across different settings.

Comprehensive vaccination strategies are urgently needed to address this gap and convert vaccination intentions into actual coverage [11,49]. Such efforts are vital as individuals who initially intend to vaccinate but remain unvaccinated are at high risk of vaccine hesitancy or refusal over time [50,51]. Therefore, effective public health interventions must extend beyond promoting acceptance to include practical measures that improve vaccine accessibility, overcome logistical challenges, and strengthen community trust in vaccination programs.

Closing this implementation gap is especially crucial given Mpox's severe health consequences in the DRC, where vulnerable populations - including children and immuno-compromised individuals - experience high rates of morbidity and mortality. The clinical management of Mpox is further complicated by frequent coinfections with varicella-zoster virus, underscoring the urgent need for effective vaccination programs [10,52].

Strength and limitations

This systematic review and meta-analysis provide a comprehensive synthesis of Mpox vaccination trends in the DRC over five decades, offering valuable insights into temporal patterns, geographic disparities, and implementation gaps through robust analysis of 18 diverse studies. However, this review has several limitations. The small number of included studies for Mpox vaccine acceptance (□3). Additionally, the small sample sizes in some subgroup analyses resulted in wide confidence intervals, limiting the precision of the findings. The predominance of non-probabilistic surveillance data might limit the inference. In addition, the vaccination status relied primarily on individual reports or the presence of a scar of vaccination instead of the presentation of a vaccination card testifying to the reception of the vaccine. Due to small number of studies assessing Mpox vaccine acceptance in DRC, further statistical analyses were not performed. Despite these limitations,

Conclusions

This systematic review revealed critical findings about Mpox vaccination in the DRC. A dramatic decline in coverage from 1970 to 2024 signals systemic failures in maintaining population immunity, particularly after the

global strategy to eradicate smallpox. The stark disparity between vaccine acceptance and actual uptake highlights substantial implementation gaps beyond willingness. Geographic inequities, with Northwest zones achieving higher coverage than Central and armed conflict regions, underscore how conflict and healthcare access shape vaccination outcomes. Two main priorities identified include targeted campaigns for underserved areas like Sankuru and Tshopo provinces to convert acceptance into uptake through community-engaged delivery models. As Mpox continues to evolve and poses a public health threat in this endemic focus, these results provide both a warning and a roadmap to close the vaccination gaps before the outbreak escalates beyond control. Future success will require integrating these empirical findings with local knowledge to build equitable, sustainable protection for all communities.

Abbreviations

CI: Confidence interval

DRC: Democratic Republic of Congo

HCW: Healthcare worker

MeSH: Medical subject headings

Mpox: Monkeypox

PRISMA: Preferred reporting items for systematic reviews and meta-analysis

Declarations

Ethical approval and consent to participate: Not applicable.

Consent for publication: Not applicable.

Availability of data and materials: The sources of data supporting this systematic review are available in the reference. All data generated or analyzed during this study are included in this published article and supplemental material.

Competing interests: All authors declare no conflicts of interest and have approved the final version of the article.

Funding source: This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Author contributions: F.Z.L.C. conceived the original idea of the study. F.Z.L.C and C.A. conducted the literature search. F.Z.L.C., C.A. and A.A. selected the studies, extracted the relevant information, and synthesized the data. F.Z.L.C., A.A.U. and S.N. performed the analyses. F.Z.L.C. wrote the first draft of the manuscript. All authors critically reviewed and revised successive drafts of the manuscript. All authors read and approved the final manuscript.

Acknowledgements: None.

References

1. Petersen BW, Kabamba J, McCollum AM, Lushima RS, Wemakoy EO, Muyembe Tamfum JJ, *et al.* Vaccinating against monkeypox in the Democratic Republic of the Congo. *Antiviral Res.* 2019; 162:171–7.

2. Breman JG, Kalisa-Ruti, Steniowski MV, Zanotto E, Gromyko AI, Arita I. Human monkeypox, 1970-79. *Bull World Health Organ.* 1980;58(2):165–82.

3. Grose C. Surveillance of Nigerian children suggests that varicella may be a risk factor for acquisition of monkeypox. *Front Public Health.* 2023; 11:1140956.

4. Fetensa G, Tolossa T, Besho M, Yadesa G, Gugsa J, Tufa DG, *et al.* Willingness to take Mpox vaccine and associated factors among health professionals in Ethiopia: A cross-sectional study. *Vaccine.* 2025 ;49:126822.

412 5. Du M, Deng J, Yan W, Liu M, Liang W, Niu B, *et al.* Mpox vaccination hesitancy, previous immunisation
413 coverage, and vaccination readiness in the African region: a multinational survey. *eClinicalMedicine*. 2025;
414 80:103047.

415 6. Sah R, Padhi BK, Siddiq A, Abdelaal A, Reda A, Ismail Lashin B, *et al.* Public Health Emergency of
416 International Concern declared by the World Health Organization for Monkeypox. *Glob Secur Health Sci*
417 *Policy*. 2022;7(1):51–6.

418 7. Ongoing Clade II Mpox Global Outbreak. CDC, Atlanta. 2025.
419 https://www.cdc.gov/mpox/outbreaks/2022/index-1.html. Accessed 2025 May 20.

420 8. Olawade DB, Wada OZ, Fidelis SC, Oluwole OS, Alisi CS, Orimabuyaku NF, *et al.* Strengthening
421 Africa's response to Mpox (monkeypox): insights from historical outbreaks and the present global
422 spread. *Sci One Health*. 2024; 3:100085.

423 9. Mitjà O, Alemany A, Marks M, Mora JIL, Rodríguez-Aldama JC, Silva MST, et al. Mpox in people with
424 advanced HIV infection: a global case series. *The Lancet*. 2023;401(10380):939–49.

425 10. Cheuyem FZL, Zemsi A, Ndungo JH, Achangwa C, Takpando-le-grand DR, Goupeyou-Youmsi J, *et al.*
426 Mpox severity and mortality in the most endemic focus in africa: a systematic review and meta-analysis
427 (1970-2024). *medRxiv*; 2025. doi:10.1101/2025.04.07.25325410v2.

428 11. Petrichko S, Kindrachuk J, Nkamba D, Halbrook M, Merritt S, Kalengi H, *et al.* Mpox Vaccine
429 Acceptance, Democratic Republic of the Congo. *Emerg Infect Dis*. 2024;30(12):2614–9.

430 12. Shafaati M, Forghani S, Shahsavand Davoudi A, Samiee R, Mohammadi K, Akbarpour S, *et al.* Current
431 advances and challenges in mpox vaccine development: a global landscape. *Ther Adv Vaccines Immunother*.
432 2025; 13:25151355251314339.

433 13. Wang X, Gu Z, Sheng S, Song R, Jin R, Beijing Key Laboratory of Emerging Infectious Diseases,
434 Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China, *et al.*
435 The Current State and Progress of Mpox Vaccine Research. *China CDC Wkly.* 2024;6(7):118–25.

436 14. Poland GA, Kennedy RB, Tosh PK. Prevention of monkeypox with vaccines: a rapid review. *Lancet Infect*
437 *Dis.* 2022;22(12): e349-58.

438 15. Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu Territory,
439 Democratic Republic of the Congo. *Bull World Health Organ.* 1972;46(5):593–7.

440 16. Brosius I, Vakaniaki EH, Mukari G, Munganga P, Tshomba JC, Vos ED, et al. Epidemiological and
441 clinical features of mpox during the clade Ib outbreak in South Kivu, Democratic Republic of the
442 Congo: a prospective cohort study. *The Lancet.* 2025;405(10478):547–59.

443 17. Vakaniaki EH, Kacita C, Kinganda-Lusamaki E, O'Toole Á, Wawina-Bokalanga T, Mukadi-Bamuleka D,
444 *et al.* Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the
445 Congo. *Nat Med.* 2024;30(10):2791–5.

446 18. Jezek Z, Marennikova SS, Mutumbo M, Nakano JH, Paluku KM, Szczeniowski M. Human Monkeypox:
447 A Study of 2,510 Contacts of 214 Patients. *J Infect Dis.* 1986;154(4):551–5.

448 19. McCollum AM, Nakazawa Y, Ndongala GM, Pukuta E, Karhemere S, Lushima RS, *et al.* Human
449 Monkeypox in the Kivus, a Conflict Region of the Democratic Republic of the Congo. *Am Soc Trop Med*
450 *Hyg.* 2015;93(4):718–1.

451 20. Whitehouse ER, Bonwitt J, Hughes CM, Lushima RS, Likafi T, Nguete B, *et al.* Clinical and
452 Epidemiological Findings from Enhanced Monkeypox Surveillance in Tshuapa Province, Democratic
453 Republic of the Congo During 2011–2015. *J Infect Dis.* 2021 ;223(11) :1870–8.

454 21. Dieu-Merci. KY, Singa Valentin. B, Ley. BL, Antoine. ET, Guild. AK, Lwanga. K, *et al.* MPOX:
455 EPIDEMIOLOGICAL PROFILE AND FACTORS ASSOCIATED WITH ITS EMERGENCE IN

456 THE ISANGI TERRITORY, DEMOCRATIC REPUBLIC OF CONGO. *Int J Appl Sci Eng Rev.*
457 2024;5(5):27–43.

458 22. Makali SL, St Louis P, Karemere H, Wautié A, Pavignani E, Eboma CM, *et al.* Exploring the inherent
459 resilience of health districts in a context of chronic armed conflict: a case study in Eastern Democratic
460 Republic of the Congo. *Health Res Policy Syst.* 2024;22(1):1–15.

461 23. Djuicy DD, Selekon B, Malaka C, Soumah A, Adjogoua E, Kadjo H, *et al.* Strengthening Africa's
462 resilience to Mpox: Preparedness and response initiatives of the Pasteur network. *J Public Health Afr.*
463 2025;16(1):1026.

464 24. Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred Reporting Items for Systematic
465 Reviews and Meta-Analyses: The PRISMA Statement. *PLOS Med.* 2009;6(7): e1000097.

466 25. Congo, Democratic Republic of the. In: The World Factbook. Central Intelligence Agency; 2023.
467 https://www.cia.gov/the-world-factbook/countries/congo-democratic-republic-of-the/. Accessed 2023
468 Oct 30.

469 26. Tati G. Territory and border crossing for livelihoods among (voluntary and forced) migrants from DRC
470 to Swaziland: the re-imagining of a borderless spatial system. In: Udelsmann Rodrigues C, Tomàs J,
471 editors. Crossing African Borders: Migration and Mobility. Lisboa : Centro de Estudos Internacionais;
472 2012. p. 126–44. (ebook'IS).

473 27. République démocratique du Congo - Plan national de développement sanitaire recadré pour la période
474 2019-2022 : Vers la Couverture sanitaire universelle.
475 https://www.ilo.org/dyn/natlex/natlex4.detail?p_isn=111796&p_lang=fr. Accessed 2023 Oct 30.

476 28. Democratic Republic of the Congo. WHO, Geneva. 2024. https://data.who.int/countries/180.
477 Accessed 2025 Mar 27.

478 29. Amani A, Bene ACM, Lungoyo CL, Mukoka AK, Cheuyem FZL, Mpinganjira S, *et al.* The Struggle to
479 Vaccinate: Unveiling the Reality of the first year of Covid-19 Vaccination in the Democratic Republic
480 of Congo. *medRxiv*; 2024. doi: 10.1101/2024.01.03.24300795v1.

481 30. Overview. World Bank. 2023. Https://www.worldbank.org/en/country/drc/overview. Accessed 2023
482 Oct 30.

483 31. Democratic Republic of the Congo situation. UNHCR, Global Focus, Geneva. 2024.
484 Https://reporting.unhcr.org/operational/situations/democratic-republic-congo-situation. Accessed
485 2025 Apr 6.

486 32. JBI Critical Appraisal Tools. The Joanna Briggs Institute, Adelaide. 2017. https://jbi.global/critical-
487 appraisal-tools. Accessed 2024 Dec 3.

488 33. Sulaiman SK, Isma'il Tsiga-Ahmed F, Musa MS, Makama BT, Sulaiman AK, Abdulaziz TB. Global
489 prevalence and correlates of mpox vaccine acceptance and uptake: a systematic review and meta-
490 analysis. *Commun Med.* 2024;4(1):136.

491 34. Stijnen T, Hamza TH, Ozdemir P. Random effects meta-analysis of event outcome in the framework of
492 the generalized linear mixed model with applications in sparse data. *Stat Med.* 2010;29(29):3046–67.

493 35. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical
494 Computing, Vienna, Austria. 2024. https://www.R-project.org/. Accessed 2024 Dec 19.

495 36. Mutombo M, Jezek Z, Arita I, Jezek Z. HUMAN MONKEYPOX TRANSMITTED BY A
496 CHIMPANZEE IN A TROPICAL RAIN-FOREST AREA OF ZAIRE. *Lancet Lond Engl.*
497 1983;321(8327):735–7.

498 37. Jezek Z, Szczeniowski M, Paluku KM, Mutombo M. Human Monkeypox: Clinical Features of 282
499 Patients. *J Infect Dis.* 1987;156(2):293–8.

500 38. Mwanba PT, Tshioko KF, Moudi A, Mukinda V, Mwema GN, Messinger D, *et al.* Human monkeypox in
501 Kasaï Oriental, Zaire (1996-1997). *Eurosurveillance.* 1997;2(5):33–5.

502 39. Hutin YJF, Williams RJ, Malfait P, Pebody R, Loparev VN, Ropp SL, *et al.* Outbreak of Human
503 Monkeypox, Democratic Republic of Congo, 1996 to 1997. *Emerg Infect Dis.* 2001;7(3):434–8.

504 40. Aplogan A, Mangindula V, Muamba P, Mwema G, Okito L, Pebody R, *et al.* Human monkeypox -- Kasai
505 Oriental, Democratic Republic of Congo, February 1996-October 1997. *MMWR Morb Mortal Wkly Rep.*
506 1997;46(49):1168–71.

507 41. Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, *et al.* Major
508 increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the
509 Democratic Republic of Congo. *Proc Natl Acad Sci.* 2010;107(37):16262–7.

510 42. Nolen LD, Osadebe L, Katomba J, Likofata J, Mukadi D, Monroe B, *et al.* Extended Human-to-Human
511 Transmission during a Monkeypox Outbreak in the Democratic Republic of the Congo. *Emerg Infect Dis.*
512 2016;22(6):1014–21.

513 43. Mande G, Akonda I, Weggheleire AD, Brosius I, Liesenborghs L, Bottieau E, et al. Enhanced
514 surveillance of monkeypox in Bas-Uélé, Democratic Republic of Congo: the limitations of symptom-
515 based case definitions. *Int J Infect Dis.* 2022; 122:647–55.

516 44. Dagovetz M, Momchilov K, Blank L, Khorsandi J, Rizzo A, Khabbache H, et al. Global COVID-19
517 vaccination challenges: Inequity of access and vaccine hesitancy. *J Med Surg Public Health.* 2025; 6:100197.

518 45. Fousseni S, Ngangue P, Barro A, Ramde SW, Bihina LT, Ngoufack MN, et al. Navigating the Road to
519 Immunization Equity: Systematic Review of Challenges in Introducing New Vaccines into Sub-Saharan
520 Africa's Health Systems. *Vaccines.* 2025;13(3):269.

521 46. Adigun OA, Okesanya OJ, Ahmed MM, Ukoaka BM, Lucero-Prisno DE, Onyeaghala EO, *et al.*
522 Syndemic Challenges: Addressing the Resurgence of Mpox Amidst Concurrent Outbreaks in the DRC.
523 Zheng C, editor. *Transbound Emerg Dis.* 2024;2024(1):1962224.

524 47. Mpox. WHO, Geneva. 2024. Https://www.who.int/news-room/fact-sheets/detail/mpox. Accessed
525 2025 Apr 27.

526 48. Abdelouahed M, Yateem D, Amzil C, Aribi I, Abdelwahed EH, Fredericks S. Integrating artificial
527 intelligence into public health education and healthcare: insights from the COVID-19 and monkeypox
528 crises for future pandemic readiness. Front Educ. 2025; 10:1518909.

529 49. Cheuyem FZL, Amani A, Nkodo ICA, Boukeng LBK, Edzamba MF, Nouko A, *et al.* COVID-19
530 vaccine acceptance and hesitancy in Cameroon: a systematic review and meta-analysis. *BMC Public*
531 *Health.* 2025;25(1):1035.

532 50. Loomba S, de Figueiredo A, Piatek SJ, de Graaf K, Larson HJ. Measuring the impact of COVID-19
533 vaccine misinformation on vaccination intent in the UK and USA. *Nat Hum Behav.* 2021;5(3):337–48.

534 51. Cheuyem FZL, Amani A, Achangwa C, Ajong BN, Minkandi CA, Zeh MMMK, *et al.* COVID- 19
535 vaccine uptake and its determinants in Cameroon: a systematic review and meta-analysis (2021–2024).
536 *BMC Infect Dis.* 2025;25(1):525.

537 52. Cheuyem FZL, Asahngwa C, Bakari WN, Achangwa C, Goupeyou-Youmsi J, Ajong BN, et al. Mpox
538 clinical features and varicella-zoster virus coinfection in the Democratic Republic of Congo: a
539 systematic review and meta-analysis (1970-2024). *medRxiv*; 2025. doi: 10.1101/2025.05.02.25326902v1.

540

Table 1 Characteristic of studies assessing Mpox vaccination in DRC, 1970-2024

Author	Study Year[1]	Region	Setting	Study population	Study type	Sampling	Risk of bias	Outcome of interest	Sample size vaccination survey	Summary of findings
Ladnyj *et al.* [15]	1970	Equateur	Community	General population	Cross-sectional	Non-probabilistic	Low	Vaccine uptake	1132	The unvaccinated young patient's relatives and most villagers showed signs of smallpox vaccination or previous infection.
Breman *et al.* [2]	1979	Equateur	Community	General population	Cross-sectional	Non-probabilistic	Low	Vaccine uptake	38	Of the 47 reported cases in Central and West Africa, 38, representing the vast majority, occurred in Zaire. These cases, largely in children under 10, presented with a 17% case-fatality rate.
Mutombo *et al.* [36]	1982	South Kivu	Community	General population	Cross-sectional	Non-probabilistic	Low	Vaccine uptake	1367	The rash's onset was consistent with chimpanzee transmission, but the primary monkeypox reservoir remained unknown.
Jezek *et al.* [18]	1984	Nationwide	Community	General population	Cross-sectional	Non-probabilistic	Low	Vaccine uptake	2083	A study of 2,510 contacts of monkeypox patients revealed a significant number of secondary cases, primarily in children, with waning immunity observed in vaccinated individuals, though vaccination still offered considerable protection.
Jezek *et al.* [37]	1985	Nationwide	Community	General population	Cross-sectional	Non-probabilistic	Low	Vaccine uptake	282	unvaccinated individuals, particularly young children, experienced an 11-15% case-fatality rate, while vaccinated individuals showed no deaths and altered disease presentation.
Mwamba *et al.* 38]	1997	Kasai Oriental	Community	General population	Cross-sectional	Non-probabilistic	Low	Vaccine uptake	84	The 1996-97 investigation suggested most monkeypox cases resulted from person-to-person transmission, a shift from earlier reports of primarily animal-to-human spread.
Hutin *et al.* 39]	1997	Sankuru	Community	General population	Cross-sectional	Non-probabilistic	Low	Vaccine uptake	84	This outbreak presented with notable attack and case-fatality rates. The cessation of smallpox vaccination in 1983, following global eradication, contributed to an increased population susceptibility to monkeypox.
Aplogan *et al.* [40]	1997	Kasai Oriental	Community	General population	Cross-sectional	Non-probabilistic	Low	Vaccine uptake	339	There was a high prevalence of Mpox among children and a mix of primary and secondary transmission patterns across numerous villages. The outbreak was localized outbreaks and travel, close contact within households and neighborhoods facilitated the secondary case transmission.
Rimoin *et al.* [41]	2007	Sankuru	Community	General population	Cross-sectional	Non-probabilistic	Low	Vaccine uptake	760	This study revealed a dramatic increase in cases, likely due to the cessation of smallpox vaccination and the subsequent rise in a immunologically naive population.
Nolen *et al.* [42]	2012	Tshuapa	Hospital	General population and healthcare worker	Cross-sectional	Non-probabilistic	Low	Vaccine acceptance and uptake	148	Half of possible cases were lab-confirmed monkeypox. 50% household attack rate, multiple family transmissions, and a mean 8-day incubation period (4-14 days) were observed.
Petersen *et al.* [1]	2014	Tshuapa	Community	Healthcare worker	Cross-sectional	Non-probabilistic	Low	Vaccine uptake and acceptance	14	These findings suggest that while a smallpox vaccination scar may offer some protection against monkeypox, healthcare workers remain at risk of infection. The presence of co-infections further complicates the picture.
McCollum *et al.* 19]	2014	Kivu (North and South)	Community	General population	Cross-sectional	Non-probabilistic	Low	Vaccine uptake	30	Report of the first confirmed cases of monkeypox (Mpox) in forested areas of North and South Kivu Provinces, which aligns with ecological predictions for suitable Mpox transmission zones.
Whitehouse *et al.* [20]	2014	Tshuapa	Community	General population	Cross-sectional	Non-probabilistic	Low	Vaccine uptake	1057	Increased incidence compared to previous decades, likely due to waning smallpox immunity. While males generally had higher infection rates, females reported frequent contact with symptomatic individuals. Animal exposures were most common in males.
Mande *et al.* [43]	2019	Bas-Uélé	Community	General population	Cross-sectional	Non-probabilistic	Low	Vaccine uptake	71	Among 77 suspected cases, PCR revealed 27.3% monkeypox, 58.4% chickenpox, and 14.3% negative. Monkeypox cases showed distinct skin lesions.

Brosius *et al.* [16]	2024	South Kivu	Hospital	General population	Cohort	Non-probabilistic	Moderate	Vaccine uptake	308	Most suspected cases were PCR-positive for Mpox. Most cases reported contact with known Mpox, primarily spouses/partners in adults and family in children. Genital lesions were common in adults. Hospitalized mortality was low.
Petrichko *et al.* [11]	2024	Nationwide	Community	General population	Cross-sectional	Non-probabilistic	Moderate	Vaccine acceptance	5226	In the DRC, 61% accepted a Mpox vaccine, with higher rates among healthcare workers and in endemic regions.
Kombozi *et al.* [21]	2024	Tshopo	Community	General population	Cross-sectional	Probabilistic	Low	Vaccine uptake	460	Occupational activities, such as hunting and agriculture, alongside economic vulnerability and direct exposure to infected animals or individuals, play a significant role in Mpox transmission. These results underscore the complex interplay between human behavior, environmental interaction, and disease spread.
Vakaniaki *et al.* [17]	2024	South Kivu	Community	General population	Cross-sectional	Non-probabilistic	Low	Vaccine uptake	241	The Mpox outbreak in eastern DRC was caused by a distinct Clade I Mpox lineage, differing from historical zoonotic patterns. The outbreak, predominantly affected young adults including a significant proportion of female sex workers, suggests a shift towards human-to-human transmission, potentially involving sexual contact.

[1] Date of study completion; HCW: Healthcare worker; DRC: Democratic Republic of Congo; PCR: Polymerase chain reaction